Press release content from Business Wire. The AP news staff was not involved in its creation.
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
March 2, 2021 GMT
NEW HAVEN, Conn. (BUSINESS WIRE) Mar 2, 2021
Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the details of two previously undisclosed pipeline programs. RLYB212 is a novel monoclonal antibody to human platelet antigen (HPA)-1a in preclinical development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disorder that can cause uncontrolled bleeding in fetuses and newborns. RLYB116 is a small protein inhibitor of complement factor 5 (C5) suitable for subcutaneous administration in preclinical development for the treatment of patients
By Natalie Missakian
Just 10 months after Rallybio launched in early 2018, Fierce Biotech, an international trade journal widely followed in the bioscience world, dubbed it one of the year’s 15 most promising biotechs.
The New Haven-based company had yet to make any groundbreaking discoveries. In fact, it didn’t have a single drug in its portfolio. And outside of its announced focus on treatments for severe rare diseases, Rallybio’s founders had offered few details about what medical conditions the startup planned to pursue.
Still, the company was getting noticed not only by reporters covering the industry but also by investors as evidenced by the $37 million it raised shortly after setting up its first lab and office at UConn’s Technology Incubation Program (TIP) in Farmington.
(Pixabay)
Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word or the bad from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week.
Another GSK vaccine exec jumps ship for biotech CEO role
GlaxoSmithKline
Amir Reichman is stepping down.
Reichman is leaving his post as head of global vaccines engineering core technology at GSK to eventually head up operations at BiondVax Pharmaceuticals. Reichman will split duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he wraps his time at GSK. Reichman joined GSK in 2015 as part of a multibillion-dollar deal that saw GSK trade off its oncology assets for Novartis’ vaccines unit. Reichman held various positions at Novartis in its vaccine supply chain unit before becoming director of GSK’s global vaccines supply chain and then head of global vaccines engineering
Press release content from Business Wire. The AP news staff was not involved in its creation.
Steven Tuch Joins Rallybio to Lead Corporate Development
January 21, 2021 GMT
NEW HAVEN, Conn. (BUSINESS WIRE) Jan 21, 2021
Rallybio LLC, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Steven Tuch to lead the Company’s corporate development function. In this role, Mr. Tuch, a seasoned healthcare business professional, will have responsibility for Rallybio’s financing and capital allocation strategies and will also partner with the Business Development team to review and assess opportunities for transformative corporate deals, partnerships, and acquisitions.